Peter Nielsen

Peter Nielsen co-founded Bio-Path Holdings, a public biotechnology company developing targeted oncology therapies, and currently serves as Bio-Path’s President, Chief Executive Officer, Chief Financial Officer and Chairman of the Board of Directors. At the time of Bio-Path’s establishment in 2007, Mr. Nielsen licensed technology and targets from the University of Texas M.D. Anderson Cancer Center and coordinated preclinical development, optimization and manufacturing of Bio-Path’s lead product, BP1001. Over the next ten years, Mr. Nielsen led the clinical advancement of BP1001 into Phase 2 studies, the introduction of additional pipeline candidates, and the company’s public market debut. Prior to co-founding Bio-Path, Mr. Nielsen has worked with several other companies, leading turnarounds and developing and executing on strategies for growth. He currently serves as a director of Bio-Path and of Synthecon, Inc., a company developing 3D cell culture technology. Before entering the biotechnology sector, Mr. Nielsen was a lieutenant in the U.S. Naval Nuclear Power program where he was director of the physics department, and was employed at Ford Motor Company in product development. Mr. Nielsen has a broad background in senior management and has significant negotiating experience. He has earned degrees in engineering, mathematics and an MBA in finance from the University of California at Berkeley.